Stay updated with breaking news from Amanda Sheldon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 139.4% of children...
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement ...
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 139.4% of children...
These findings are the first to characterize the unique molecular profile of seborrheic dermatitis...
WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,